A common sugar found in a wide variety of everyday foods and sweetened beverages may play a previously unrecognized and unexpected role in helping aggressive forms of ovarian cancer spread throughout the body. Researchers at The Wistar Institute have discovered that cancer cells managing to survive grueling rounds of chemotherapy can actually release fructose into their microenvironment. This biological byproduct then acts as a potent signaling molecule, encouraging nearby tumor cells to break free from their original locations and initiate the metastatic process.
The findings, which have been published in the scientific journal Nature Aging, shed light on an entirely novel mechanism through which cancer cells can continue to influence tumor progression and behavior, even long after medical treatment has successfully halted their ability to multiply. Furthermore, this groundbreaking discovery raises critical new questions regarding whether dietary sugar consumption—as well as commonly prescribed cholesterol-lowering medications—might influence how cancer advances in the human body.
"Some cancer cells that survive chemotherapy aren’t dividing anymore, but they’re still biologically active," explained Aidan Cole, Ph.D., a postdoctoral fellow working in the laboratory of Katherine Aird, Ph.D., at The Wistar Institute and the first author on the new study. "Instead, they continue to release molecules that send signals to nearby cells. Our study is among the first to show that a nutrient—in this case, fructose—can act as one of those signals."
Why Ovarian Cancer Often Returns After Chemotherapy
The vast majority of patients diagnosed with ovarian cancer receive platinum-based chemotherapy as a primary line of defense. This standard treatment utilizes specialized drugs containing platinum designed to damage the DNA of rapidly dividing cancer cells, thereby preventing them from reproducing and shrinking the overall tumor mass. Although a significant number of patients initially respond quite favorably to this regimen, the cancer ultimately returns in the majority of cases.
When the disease recurs, it frequently does so in a disseminated pattern throughout the abdominal cavity—the complex anatomical space inside the abdomen that houses vital internal organs such as the stomach, intestines, and liver. This destructive spread, scientifically known as metastasis, is clinically devastating and is directly responsible for approximately 90% of all ovarian cancer-related deaths. Because of this grim statistic, understanding the precise mechanisms that allow cancer cells to escape from their original tumor site and establish secondary colonies elsewhere is considered a paramount priority for cancer researchers worldwide.
Prior scientific investigations have hinted at the possibility that cancer cells surviving chemotherapy might actively contribute to disease recurrence, even when they are technically dormant and no longer actively dividing. These persistent cells are capable of synthesizing and releasing a complex cocktail of biological substances that can profoundly alter the behavior and characteristics of surrounding, healthy, or malignant cells.
To investigate this intricate biological process in depth, Cole and his multidisciplinary team of colleagues designed an innovative experiment that successfully separated surviving cancer cells from the specific signaling molecules they released into their surroundings. To their astonishment, the researchers discovered that these released substances, acting entirely independently of the surviving cells themselves, were more than sufficient to significantly increase cancer spread when tested in a preclinical model.
"As far as we know, this is the first time anyone has shown, in a preclinical model rather than just a dish, that it’s the molecules these cells release—not the cells themselves—that drive the cancer’s spread," Cole noted.
A Common Sugar Emerges as a Surprising Cancer Signal
With the realization that secreted molecules were driving metastasis, the next major challenge for the research team was identifying the precise substances responsible for encouraging the cancer cells to break loose and migrate. Through rigorous analysis, the investigators uncovered an unexpected and ubiquitous culprit: fructose.
Fructose is a naturally occurring simple sugar found abundantly in fresh fruits, honey, and various other whole foods. However, it is also a major component of standard table sugar, as well as high-fructose corn syrup, an artificial sweetener that is heavily utilized across the modern food industry in soft drinks, baked goods, and an expansive array of processed foods.
The new study revealed that ovarian cancer cells surviving chemotherapy could actively manufacture fructose and secrete it into their immediate surroundings. Rather than simply serving as a traditional metabolic energy source to fuel cellular work, the sugar took on an entirely different role, acting as a chemical messenger that actively encouraged neighboring cancer cells to acquire enhanced migratory and invasive capabilities.
Perhaps most concerningly, the researchers uncovered another troubling possibility during their preclinical experiments. They observed that consuming high amounts of fructose—levels directly comparable to those routinely found in sugary beverages in the modern Western diet—could actively promote signaling pathways associated with cancer spread, even in the complete absence of prior chemotherapy treatment.
This critical observation strongly suggests that a person’s routine diet might influence cancer progression and metastasis through a biochemical mechanism that scientists had previously failed to recognize. Fructose consumption is an especially relevant public health consideration in the United States, where high-fructose corn syrup can account for roughly 8% to 20% of an individual’s total daily calorie intake.
Unlike many inherent risk factors that influence cancer susceptibility and disease progression, dietary fructose intake is a modifiable lifestyle factor. This raises the intriguing long-term possibility that targeted nutritional strategies might eventually become integrated into comprehensive clinical efforts to limit cancer metastasis.
Nevertheless, the researchers urge caution and emphasize significant caveats. Scientists have not yet tested whether actively reducing dietary fructose consumption improves clinical outcomes in human patients diagnosed with ovarian cancer. Furthermore, the current findings do not establish a definitive causal link proving that eating dietary sugar directly causes cancer to spread in humans, highlighting the urgent need for additional clinical research before any specific dietary guidelines or recommendations can be formulated based on this newly discovered mechanism.
How Fructose Helps Cancer Cells Break Free
To decipher the exact cellular mechanisms by which fructose encourages cancer spread, the researchers conducted a deep dive into the microscopic changes occurring inside cancer cells when exposed to the sugar. They deployed a battery of advanced molecular biology techniques, including a sophisticated CRISPR screen, which allows scientists to systematically turn off and evaluate genes to identify precisely which ones drive a specific cellular process.
The results of these meticulous experiments revealed a striking chain of events: exposure to fructose actively suppresses the production of cholesterol in neighboring cancer cells.
Although cholesterol is most frequently discussed in the public sphere in connection with cardiovascular disease and heart health, it also performs indispensable physiological functions throughout virtually every tissue in the human body. Notably, cholesterol is a critical structural component of cell membranes—the delicate outer boundaries that enclose cells and govern how they sense, communicate, and interact with their surrounding microenvironment.
In the context of epithelial tissues and solid tumors, cholesterol helps maintain the strong intercellular connections and adhesion molecules that physically bind neighboring cells together. These specialized junctions function similarly to a biological glue, creating tight structural cohesion that makes it mechanically difficult for individual cancer cells to detach from one another.
When fructose downregulates cholesterol production, however, these crucial intercellular connections weaken significantly. Consequently, the cancer cells lose their grip on one another, allowing them to detach much more easily from the primary tumor mass. This loss of cellular adhesion provides a clear physical pathway for the cells to escape their local environment, invade surrounding tissues, and spread to distant anatomical locations.
This novel discovery provides a compelling mechanistic explanation for how a common nutritional component can directly influence one of the most dangerous and lethal hallmarks of malignant disease.
A Surprising Connection Between Statins and Cancer Spread
The unexpected finding regarding cholesterol production also prompted the research team to investigate a parallel and highly relevant clinical question involving statins—a class of medications that are among the most widely prescribed drugs in the world for lowering cholesterol levels.
In the United States alone, approximately 39 million people take statins on a regular basis. These pharmaceuticals work by inhibiting an essential enzyme in the liver to reduce the body’s endogenous production of cholesterol, and they are routinely prescribed by physicians to mitigate the risk of heart attacks and strokes in at-risk populations.
Because the Wistar team observed that fructose promoted cancer metastasis precisely by suppressing cholesterol production, they wanted to determine whether statins might inadvertently produce a similar biological effect on tumor cells.
To answer this, the researchers tested statins in their experimental models and discovered that the drugs alone could indeed weaken the adhesive connections between cancer cells, making it substantially easier for them to separate and escape.
This provocative finding raises critical questions regarding whether commonly used cholesterol-lowering medications might unintentionally influence the efficacy of chemotherapy or alter metastatic risk in specific clinical scenarios. While researchers are actively pursuing further studies to explore this possibility, they strongly emphasize that these results have not yet been demonstrated in human patients and should not be interpreted as a reason for anyone to stop taking their prescribed statins.
"We haven’t tested this effect in patients yet, but it raises questions about combining cholesterol-lowering drugs with chemotherapy, especially since ovarian cancer is most common in postmenopausal women who are often already on statins," said Katherine Aird, Ph.D., professor and co-leader of the Molecular and Cellular Oncogenesis Program in the Ellen and Ronald Caplan Cancer Center at The Wistar Institute, and senior author of the study.
Could Fructose Also Help Other Cancers Spread?
Although the scope of the newly published research focused primarily on epithelial ovarian cancer, the scientists strongly suspect that this exact biological pathway may not be unique to a single malignancy. They hypothesize that similar mechanisms could operate in various other forms of cancer, particularly those originating within the torso and abdominal cavity.
Malignancies affecting internal organs situated close to one another frequently exhibit patterns of local invasion and metastasis to adjacent tissues and surrounding organs. If dietary fructose and cellular signaling molecules impact intercellular adhesion in other tumor types similarly, the broader implications of this discovery could extend far beyond ovarian cancer alone.
"We think other cancers that spread within the torso—pancreatic, colon, liver—could behave similarly. We can’t call it universal yet, but we think the effects are not just limited to ovarian cancer," Aird said.
Building upon their initial success, Aird and Cole have already initiated the design of subsequent experimental phases aimed at determining whether these findings can be successfully replicated across pancreatic, colorectal, hepatic, and other visceral cancers.
The research opens an entirely new chapter in scientific understanding regarding how tumors manage to survive aggressive medical interventions and subsequently drive metastatic relapse. It also highlights the intricate, often underappreciated complexity of the crosstalk between basic nutrients, endogenous cholesterol metabolism, and dynamic cancer cell behavior.
While the definitive clinical implications for patient diets and existing pharmaceutical regimens remain to be fully elucidated, the identification of fructose as a key signaling agent that helps cancer cells sever their ties and escape provides researchers with a promising conceptual framework. Over time, these insights could point the scientific community toward innovative therapeutic strategies designed to block metastasis and significantly improve long-term outcomes for cancer patients.
